Neoadjuvant and Adjuvant Pembrolizumab Extends Survival in Early-Stage TNBC
KEYNOTE-522 trial in early-stage TNBC showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab improved overall survival by 34% vs chemotherapy plus placebo, with 5-year OS rates of 86.6% and 81.7%, respectively.
Reference News
Neoadjuvant and Adjuvant Pembrolizumab Extends Survival in Early-Stage TNBC
KEYNOTE-522 trial in early-stage TNBC showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab improved overall survival by 34% vs chemotherapy plus placebo, with 5-year OS rates of 86.6% and 81.7%, respectively.